SLAM family member 7 (SLAMF7) Antibody

Background

SLAMF7 (SLAM Family Member 7), also known as CS1 (CD2 subset 1) or CRACC (CD319), is a cell surface glycoprotein belonging to the Signaling Lymphocyte Activation Molecule (SLAM) family within the immunoglobulin superfamily. SLAMF7 is primarily expressed on the surface of immune cells, especially on natural killer (NK) cells, plasma cells, and certain T-cell subsets, as well as dendritic cells and monocytes. This receptor plays a key role in immune cell activation, adhesion, and signal transduction, significantly influencing immune responses. SLAMF7 is particularly relevant in the context of immune surveillance and tumor cell recognition, as it acts as a co-stimulatory molecule for NK cells, enhancing their cytotoxic function against abnormal cells. In the tumor microenvironment, SLAMF7 can either promote anti-tumor immunity or, in some cases, contribute to immune evasion mechanisms that facilitate cancer cell survival. Its expression in multiple myeloma, where it is typically highly expressed, has made it a target for immunotherapy. The development of monoclonal antibodies against SLAMF7, like elotuzumab, has underscored its significance in cancer therapy.